SCHEMBL252353

SCHEMBL252353

Cn1cc(Br)ccc1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15288929 0.82 BRD4 (0.49)
Butyric Acid SCHEMBL21550020 0.80 FFAR3 (0.42)
SCHEMBL12063 0.72
SCHEMBL19280560 0.71 BRD4 (0.62)
SCHEMBL2114660 0.70
SCHEMBL7267066 0.70
SCHEMBL7247913 0.70
Selectan SCHEMBL117423 0.70
SCHEMBL331704 0.70
SCHEMBL1158462 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 695 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124222-A1 ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-05-07 US disclosed
EP-4720065-A1 PRMT5 INHIBITORS AND USES THEREOF Insilico Medicine IP Limited (HK) 2026-04-08 EP disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 US disclosed
US-12503438-B2 Compounds for the treatment of kinase-dependent disorders EXELIXIS, INC. (US) 2025-12-23 US disclosed
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 US disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 EP disclosed
WO-2025128873-A1 HETEROCYCLIC PYRIDINONE COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2025-06-19 WO disclosed
US-20250186441-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2025-06-12 US disclosed
US-20250122171-A1 Substituted Amine Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. 2025-04-17 US disclosed
US-20250115569-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LTD (GB) 2025-04-10 US disclosed
EP-1216239-B1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2004-02-11 EP disclosed
US-6544986-B2 Such as 5-(N,N-dibenzyl)aminocarbonyl-2-pyridone; enzyme inhibitors; for treatment of Alzheimer's disease DALHOUSIE UNIVERSITY (CA) 2003-04-08 US disclosed
US-6436972-B1 HETEROCYCLIC AMIDES, USED AS ANTICHOLINERGICS AND SERINE PROTEASE STIMULANTS, FOR PROPHYLAXIS OF ALZHEIMER'S DISEASE, GLIOMAS AND VISION DEFECTS DALHOUSIE UNIVERSITY (CA) 2002-08-20 US disclosed
EP-1216239-A1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2002-06-26 EP disclosed
US-20020049330-A1 Novel pyridones and their use as modulators of serine hydrolase enzymes DALHOUSIE UNIVERSITY 2002-04-25 US disclosed
WO-2001077078-A1 NOVEL PYRIDONES AND THEIR USE AS MODULATORS OF SERINE HYDROLASE ENZYMES DALHOUSIE UNIVERSITY (CA) 2001-10-18 WO disclosed
EP-0984961-B1 NOVEL PYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2001-06-20 EP disclosed
WO-2001023374-A1 PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS SMITHKLINE BEECHAM P.L.C. (GB) 2001-04-05 WO disclosed
US-6143751-A Pyridine derivatives and pharmaceutical compositions containing them ASTRAZENECA UK LIMITED (GB) 2000-11-07 US disclosed
CN-1034715-A N-cyanogen methyl-2-pyridinone insecticides DOW CHEMICAL CO (US) 1989-08-16 CN disclosed